Lipella Pharmaceuticals I...
(LIPO)
undefined
undefined%
At close: undefined
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to
free cash flow ratio, price per earnings, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 |
Net Income | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
Depreciation & Amortization | 1.69K | - | - | - | - |
Stock-Based Compensation | 1.36M | 747.40K | 728.80K | 57.71K | - |
Other Working Capital | 237.23K | -327.93K | 175.25K | -7.48K | 24.68K |
Other Non-Cash Items | 121.20K | 9.61K | -50.21K | 7.64K | 18.73K |
Deferred Income Tax | - | - | - | - | - |
Change in Working Capital | -9.11K | 9.52K | 197.61K | -32.28K | 14.34K |
Operating Cash Flow | -3.15M | -1.83M | -989.27K | -28.58K | -39.12K |
Capital Expenditures | -14.43K | - | - | - | - |
Acquisitions | - | - | - | - | - |
Purchase of Investments | - | 300.55M | -300.55K | - | - |
Sales Maturities Of Investments | - | 300.55K | - | - | - |
Other Investing Acitivies | - | -300.55M | -300.55K | - | - |
Investing Cash Flow | -14.43K | 300.55K | -300.55K | - | - |
Debt Repayment | -275.00K | 275.00K | - | 57.04K | 25.00K |
Common Stock Repurchased | - | - | - | - | - |
Dividend Paid | - | - | - | - | - |
Other Financial Acitivies | 1.61M | - | - | - | - |
Financial Cash Flow | 1.34M | 5.24M | 2.10M | 609.31K | 25.00K |
Net Cash Flow | -1.83M | 3.71M | 807.09K | 580.73K | -14.12K |
Free Cash Flow | -3.16M | -1.83M | -989.27K | -28.58K | -39.12K |